Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA), an emerging growth company incorporated in Florida, filed this Form 8-K on May 21, 2026. The filing reports the entry into a material definitive agreement regarding its Ketamir-2 development program.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a contractual amendment.
Material Changes
On May 21, 2026, the Company entered into Amendment No. 1 to its Exclusive License Agreement with MIRALOGX LLC, originally effective November 15, 2023. Key changes include:
- Territory Expansion: The exclusive licensed territory for Ketamir-2 was expanded from the United States, Canada, and Mexico to all countries where patent rights exist.
- Patent Portfolio Expansion: The licensed portfolio now includes international patent filings and applications in the United States, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea.
- Economic Terms: The Amendment did not materially modify the core economic terms, including royalty obligations and other financial consideration, of the original agreement.
Outlook, Risks, and Management Commentary
Management states the Amendment supports the Company's global development and commercialization strategy for Ketamir-2 as it advances the program toward planned Phase 2a development. A press release announcing the execution was issued on May 27, 2026. The filing notes that the description of the Amendment is qualified by reference to the full text attached as Exhibit 10.1.
Investor Verification Checklist
- Review Exhibit 10.1 for the full text of Amendment No. 1 to verify specific patent jurisdictions and any non-economic terms.
- Confirm the status of Ketamir-2 Phase 2a development plans in subsequent filings or press releases.
- Verify that no undisclosed financial obligations were triggered by the territory expansion.
- Check the Company's cash runway given the expanded global scope of the license.